Acrivon therapeutics reports first quarter 2023 financial results and business highlights

Watertown, mass., may 09, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the first quarter ended march 31, 2023 and reviewed business highlights.
ACRV Ratings Summary
ACRV Quant Ranking